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A Live Bio-Therapeutic for Mastitis,
Containing Lactococcus lactis
DPC3147 With Comparable Efficacy
to Antibiotic Treatment
Michael Kitching1,2†, Harsh Mathur1,2†, James Flynn3, Noel Byrne3, Pat Dillon3,
Riona Sayers3, Mary C. Rea1,2, Colin Hill2,4 and R. Paul Ross1,2,4*
1 Teagasc Food Research Centre, Moorepark, Cork, Ireland, 2 APC Microbiome Ireland, University College Cork, Cork,
Ireland, 3 Teagasc Animal and Grassland Research and Innovation Centre, Moorepark, Cork, Ireland, 4 School
of Microbiology, University College Cork, Cork, Ireland
Bovine mastitis is an ongoing significant concern in the dairy and agricultural industry
resulting in substantial losses in milk production and revenue. Among the predominant
etiological agents of bovine mastitis are Staphylococcus aureus, Streptococcus uberis,
Streptococcus dysgalactiae, and Escherichia coli. Currently, the treatment of choice for
bovine mastitis involves the use of commercial therapeutic antibiotic formulations such
as TerrexineTM, containing both kanamycin and cephalexin. Such antibiotics are regularly
administered in more than one dose resulting in the withholding of milk for processing for
a number of days. Here, we describe the optimization of a formulation of Lactococcus
lactis DPC3147, that produces the two-component bacteriocin lacticin 3147, in a liquid
paraffin-based emulsion (formulation hereafter designated ‘live bio-therapeutic’) for the
first time and compare it to the commercial antibiotic formulation TerrexineTM, with a
view to treating cows with clinical/sub-clinical mastitis. Critically, in a field trial described
here, this ‘ready-to-use’ emulsion containing live L. lactis DPC3147 cells exhibited
comparable efficacy to TerrexineTM when used to treat mastitic cows. Furthermore, we
found that the L. lactis cells within this novel emulsion-based formulation remained viable
for up to 5 weeks, when stored at 4, 22, or 37◦C. The relative ease and cost-effective
nature of producing this ‘live bio-therapeutic’ formulation, in addition to its enhanced
shelf life compared to previous aqueous-based formulations, indicate that this product
could be a viable alternative therapeutic option for bovine mastitis. Moreover, the single-
dose administration of this ‘live bio-therapeutic’ formulation is a further advantage,
as it can expedite the return of the milk to the milk pool, in comparison to some
commercial antibiotics. Overall, in this field trial, we show that the live bio-therapeutic
formulation displayed a 47% cure rate compared to a 50% cure rate for a commercial
antibiotic control, with respect to curing cows with clinical/sub-clinical mastitis. The
study suggests that a larger field trial to further demonstrate efficacy is warranted.
Keywords: mastitis, emulsion, lacticin 3147, somatic cell counts, antibiotics
Abbreviations: AMR, antimicrobial resistance; APP, acute phase proteins; CFS, cell-free supernatant; cfu, colony forming
unit; ELISA, enzyme-linked immunosorbent assay; GRAS, generally regarded as safe; IL-8, interleukin 8; MRD, maximum
recovery diluent; NSAID, non-steroidal anti-inflammatory drugs; PBS, phosphate buffered saline; SCC, somatic cell counts;
WFI, water for injection; WHO, World Health Organization.
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INTRODUCTION
Mastitis is a persistent and financially important disease in dairy
cows chiefly due to the costs associated with antibiotic treatment,
discarded milk, reduced milk production and veterinary costs.
Furthermore, in the event of antibiotic treatment failure, the cows
may have to be culled. One study estimated that mastitis resulted
in a net farm profit decrease ranging between $19,132 to $91,552
per herd, predominantly due to culling cows and decreases in
milk production (Guimarães et al., 2017). Thus, decreasing the
rates of mastitis and finding effective treatment options is crucial
for ensuring a healthier herd, minimizing the likelihood of cows
with high SCC and overall maximizing the opportunities for
making profits. Antibiotic resistance (AMR) is a global problem
resulting in higher healthcare-associated costs, treatment failure
and deaths (European Centre for Disease Prevention and Control
[ECDC], 2014). Indeed, the WHO (World Health Organization)
has cited the overuse of antimicrobials in food-producing animals
as a major issue, with respect to transferable antimicrobial
resistance (Veterinary Ireland, 2014). It is therefore essential
that preventative strategies and alternative treatment plans are
devised to reduce reliance on antibiotics in the dairy herd, which
is in line with Action 6 of the European Commission’s Roadmap
against AMR (European Commission [EC], 2015).
The primary etiological agents of bovine mastitis are
Staphylococcus aureus, Streptococcus uberis and Streptococcus
dysgalactiae (Crispie et al., 2008; Zadoks et al., 2011; Abebe
et al., 2016; Bi et al., 2016). While antibiotics have proved to
be effective in some cases against mastitis, antibiotic resistance
and agents such as S. aureus which may be recalcitrant to
antibiotic therapy are major causes for concern (Barkema et al.,
2006; Melchior et al., 2006). This frequently results in a pattern
of prolonged recurrent infections within a dairy herd (Crispie
et al., 2008). To date, other forms of therapies (or combination
of antimicrobials) for mastitis have reported varying levels of
efficacy. Examples of such therapies include the combination of
lactoferrin with the antibiotic penicillin G (Diarra et al., 2002,
2003); bacteriocins such as nisin which resulted in significantly
increased cure rates amongst S. aureus infected cows (Cao et al.,
2007); immune-stimulants such as ginseng (Hu et al., 2001)
and also the use of cytokines (Barkema et al., 2006). Viable
Lactobacillus casei cells to prevent the invasion of S. aureus
into bovine mammary epithelial cells have also been utilized
(Bouchard et al., 2013). More recently, a Lactococcus culture, V7,
was found to inhibit Escherichia coli and S. aureus invasion of
bovine mammary epithelial cells (Assis et al., 2015). However,
further studies have yet to elicit their efficacy in vivo. Finally,
bacteriophage therapy with a view to treating bovine mastitis has
been hindered as a result of the inhibition of phages in bovine
milk (O’Flaherty et al., 2005).
We have already shown that the two-component bacteriocin,
lacticin 3147, produced by the lactic acid bacterium (LAB)
Lactococcus lactis DPC3147 inhibits Gram positive mastitis
pathogens (Ryan et al., 1998, 1999; Klostermann et al., 2008,
2010). L. lactis strains are routinely used as dairy starter
organisms and several strains have been granted GRAS (generally
regarded as safe) status in the dairy industry. In studies by
Ryan et al., and Twomey et al., it was demonstrated that
a combination of lacticin 3147 and bismuth-based teat seal
prevented S. dysgalactiae infection in dry cows (Ryan et al.,
1999) and S. aureus infection in lactating cows (Twomey et al.,
2000). Moreover, a freeze-dried preparation of the lacticin
3147 producing culture resuspended in sterile water was found
to be as effective as an antibiotic in curing clinical mastitis
(Klostermann et al., 2008). Since a Gram negative, lacticin
3147-insensitive E. coli strain was amongst the eliminated
pathogens described in a the study by Klostermann and co-
workers, it was postulated that some other mechanism besides
the bacteriocin was also in play (Klostermann et al., 2008).
In addition, it was demonstrated that infusion with freeze-
dried L. lactis DPC3147 rapidly stimulated the host intra-
mammary immune system triggering the influx of lymphocytes
and polymorphonuclear leukocytes (PMNs), to the mammary
gland along with the localized production of acute phase
proteins (APP). These factors in combination help clear the
mammary gland of the infecting pathogen (Crispie et al., 2008).
In this regard, it was clear that DPC3147 offers substantial
potential as a live bio-therapeutic for mastitis treatment, and
the production of low concentrations of lacticin 3147 in vivo
may contribute to the strain’s ability to induce an immune
response in the host.
The cost-prohibitive nature of producing sufficient quantities
of pure antimicrobial peptides has proved to be a stumbling
block for the use of purified antimicrobial bacteriocins to
treat bovine mastitis. Therefore, in this study, we decided to
further investigate the lacticin 3147-producing organism as a
live bio-therapeutic to treat mastitis and to compare it to an
antibiotic treatment. We describe the development of a novel
liquid paraffin-based emulsion of L. lactis DPC3147 (henceforth
termed ‘live bio-therapeutic’) with the potential as an alternative
treatment option for mastitis. We demonstrate that this ‘live
bio-therapeutic’ formulation possesses comparable efficacy to a
commercial antibiotic with respect to treating cows exhibiting
signs of clinical mastitis and/or cows with sub-clinical mastitis
with elevated SCC, abnormal milk samples and presence of
pathogens in milk.
MATERIALS AND METHODS
Preparation of Lactococcus lactis
DPC3147 Culture
A culture of L. lactis DPC3147 was maintained on LM17 agar
(Merck KGaA, Darmstadt, Germany) at 30◦C. A single colony of
DPC3147 was inoculated into 10 ml LM17 broth, and incubated
aerobically at 30◦C under static conditions overnight. One
milliliter of the overnight culture was sub-cultured into 100 ml
LM17 broth, and incubated aerobically at 30◦C overnight. This
overnight culture was centrifuged at 8000 × g for 15 min at 4◦C
and the cell pellet was then washed twice with ice cold water
for injection (WFI) (BioSciences Ltd., Dun Laoghaire, Dublin,
Ireland), and concentrated ten-fold by suspending the cells in
10 ml WFI for downstream viability assays. A schematic of the
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FIGURE 1 | Steps involved in preparation of the ‘live bio-therapeutic’ formulation and short-term viability testing of the product: (A) Flow chart of the ‘live
bio-therapeutic’ preparation including reconstitution of freeze-dried or non-freeze dried L. lactis DPC3147 cells in either WFI or liquid paraffin/polysorbate 80. The
formulation used in the animal trial is highlighted in red in the flow chart. Short-term viability of (B) non-freeze dried L. lactis DPC3147 cells stored in WFI; (C)
non-freeze dried DPC3147 cells in an emulsion (‘live bio-therapeutic’ formulation used in this study); (D) freeze-dried DPC3147 cells stored in WFI and (E)
freeze-dried DPC3147 cells in emulsion. Error bars represent standard deviations of mean values in each case.
preparation of the DPC3147 live bio-therapeutic formulation is
included in Figure 1A.
Preparation of Liquid Paraffin-Based
Emulsion Containing L. lactis DPC3147
Cells (‘Live Bio-Therapeutic’)
Pharmaceutical grade liquid paraffin and polysorbate 80 were
both purchased from Sigma Aldrich (Vale Road, Arklow,
Ireland). Polysorbate 80 (10%) was prepared in WFI and
sterilized by filtering twice through 0.2 µm syringe filters. Forty
five ml of liquid paraffin was dispensed into 250 ml glass beakers
and sterilized under dry heat at 170◦C for 2 h and allowed
to cool. Prior to preparation of the emulsion, the blade of an
Ultra-Turrax R© homogenizer was steeped in 1% v/v Chlorus and
UV-sterilized under laminar airflow for 1 h.
Ten ml cultures of L. lactis DPC3147 were grown overnight
for 16 h at 30◦C in LM17 broth. The cell pellet was isolated
from overnight cultures by centrifuging at 8000 × g for 15 min
at 4◦C using a Thermo Scientific Sorvall centrifuge. The pellets
were washed twice with 10 ml of WFI between centrifuging steps.
The cells were finally reconstituted in 15 ml of 10% polysorbate
80. Forty five ml of pure sterile liquid paraffin was blended with
15 ml of the 10% polysorbate 80 (mixed with cells) at 10000 rpm
in an Ultra-Turrax R© homogenizer under ice for 5 min to give a
final cell concentration of approximately 1 × 109 cfu per 5 ml
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dose (equivalent to 2 × 108 cfu/ml) of the emulsion. L. lactis
DPC 3147 in 10% polysorbate 80 was poured slowly into the
liquid paraffin during blending. Thus the emulsion contained a
final concentration of 2.5% polysorbate 80. A flow chart of the
preparation of the ‘live bio-therapeutic’ emulsion formulation is
included in Figure 1A.
Preparation of Freeze-Dried Culture of
L. lactis DPC3147
The culture was prepared as described above. After the final
washing step, the culture was concentrated by a factor of
10 and was freeze-dried in 1 ml aliquots in 3 ml freeze-
drying vials (Fisher Scientific, Ballycoolen, Dublin, Ireland)
using a Virtis wiz 2.0 freeze dryer overnight. Freeze-dried
cultures were reconstituted in either WFI or incorporated in
the liquid paraffin emulsion (with a final concentration of 2.5%
polysorbate 80). Pure sterile liquid paraffin was blended with
freeze dried L. lactis cells re-suspended in a final concentration
of 2.5% pharmaceutical grade polysorbate 80 at 10000 rpm in
an Ultra-Turrax R© homogenizer on ice for 5 min. L. lactis in
10% polysorbate 80 was poured slowly into the paraffin during
blending, as described above.
L. lactis DPC3147 Cell Viability Testing
The viability of the freeze dried and non-freeze dried L. lactis
DPC3147 cells in WFI and in the emulsion was examined after
storage at 4◦C, 22◦C and 37◦C. For short-term viability testing,
plate counts from the samples were conducted daily for 5 days,
while for long-term viability assays, plate counts were conducted
every 7 days for up to 35 days. Following storage, the samples
were serially diluted in maximum recovery diluent (MRD, Oxoid,
Basingstoke, Hampshire, United Kingdom) and spread-plated on
LM17 agar. Plates were incubated at 30◦C for 24h and results
expressed as cfu/ml.
Cows Selected for “Live
Bio-Therapeutic” Emulsion Formulation
Trial, Intra-Mammary Infusion and
Sampling
Holstein-Friesian dairy cows were first identified in the herd and
animals were selected for the trial based on a SCC > 250,000
cells/ml. Cows with clinical mastitis exhibited obvious signs
of inflammation and/or general malaise, clotted/abnormal milk
production and the presence of pathogens in milk. Cows
with sub-clinical mastitis did not display obvious signs of
inflammation but had SCC > 250,000 cells/ml, clotted/abnormal
milk and the presence of pathogens in milk. G∗Power calculations
prior to conducting the trial revealed that a maximum of n = 20
cows per treatment group were sufficient for statistically valid
results. To assess the efficacy of the live bio-therapeutic, cows
that were presenting with high SCC were identified in the herd
and the affected quarter infused with a one-time dose of the
‘live bio-therapeutic’ which was freshly made (approximately
1 × 109 cfu of L. lactis DPC3147 per 5 ml dose; equivalent
to 2 × 108 cfu/ml) (n = 19 quarters from 18 cows). The
control group received two doses of a commercial antibiotic
(n = 18 quarters from 15 cows), which is used for routine
treatment of lactating mastitic cows in the Moorepark herd at
the Teagasc Animal and Grassland Research and Innovation
Centre, Moorepark, Ireland, in accordance with good veterinary
practice. This commercial antibiotic is a dual antibiotic product
containing kanamycin (100,000 I.U.) and cephalexin (200 mg)
and is active against S. aureus, S. dysgalactiae, S. uberis and
E. coli. While previous field trials had utilized a commercial
antibiotic formulation containing amoxycillin, clavulanic acid
and prednisolone (Klostermann et al., 2008), here in this trial,
we utilized TerrexineTM for our control group, as this is the
antibiotic formulation that is currently used to treat mastitis in
the Moorepark herd.
All the treatments were administered directly into the teat
sinus as described previously with minor modifications (Crispie
et al., 2008; Klostermann et al., 2008). Briefly, prior to sampling,
the teat was swabbed with 70% v/v ethanol on cotton wool.
Immediately prior to infusion, a milk sample from the affected
quarter was taken. Following this, 5 ml of the emulsion-based ‘live
bio-therapeutic’ formulation containing approximately 1 × 109
cfu per 5 ml dose (equivalent to 2 × 108 cfu/ml) was infused
into the mammary gland using sterile blunt-ended steel syringes
(17 mm in length). One pre-loaded syringe of the commercial
antibiotic was infused at the morning and evening milkings
as per manufacturer’s instructions on the day of treatment.
Milk samples were taken after 6h and then at intervals up to
7 days post-infusion for analysis of SCC, interleukin (IL)-8 titres,
presence of mastitis pathogens and viable counts of L. lactis
DPC3147 in milk.
Somatic Cell Count (SCC) Measurements
SCC of milk samples were quantified as described previously
with a few minor modifications (Klostermann et al., 2008,
2010). Briefly, milk samples were taken from the relevant
quarters at time 0 (just before treatment) and at subsequent
time points post-treatment. SCC determined in raw milk
were measured using a Somacount 300 R©(Bentley Instruments
Incorporated, United States).
Quantification of IL-8 Levels in Milk
Samples Using ELISA
Milk samples were taken as described above and centrifuged at
44000 × g for 30 min to separate the fat layer from the milk,
which was removed using a sterile spatula. After centrifuging,
the supernatants from the milk samples were subjected to IL-
8 analysis by enzyme-linked immunosorbent assay (ELISA).
The bovine IL-8 (CXCL8) ELISA development kit (Mabtech
AB, Nacka Strand, Sweden) was used to measure IL-8 levels
in milk samples taken at different time points pre- and post-
treatment from cows treated with the ‘live bio-therapeutic’
emulsion preparation or the commercial antibiotic control. The
following procedure was used: A 96-well Nunc-Immuno plate
(Thermo Scientific, Ballycoolen, Dublin, Ireland) was coated with
100 µl of mAb MT8H6 at a concentration of 2 µg/ml (diluted in
PBS pH 7.4) and the plate was kept overnight in the dark for 16h
at 4◦C. The following day, all wells were washed twice with 200µl
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phosphate buffered saline (PBS). The plate was subsequently
blocked with 200 µl PBS (supplemented with 0.05% Tween 20
and 0.1% bovine serum albumin) and the plate incubated at room
temperature in the dark for 1 h. After 1h, the plate was washed
five times using PBS supplemented with 0.05% Tween 20 (wash
buffer). Following this, 100 µl of IL-8 standards ranging from
concentrations of 12.5 pg/ml to 800 pg/ml were added to the wells
in triplicate. Milk samples taken at different time points were
diluted up to 100-fold in PBS and 100µl of the undiluted samples,
1:10 dilutions and 1:100 dilutions were added to the wells in the
microtiter plate in triplicate, and the plate incubated at room
temperature in the dark for 2h. After 2h, each well was washed
five times with wash buffer. Following these wash steps, 100 µl of
mAb 26E5-biotin at a final concentration of 0.1 µg/ml was added
to each of the wells and the plate incubated at room temperature
in the dark for 1h. As before, the wells were washed with wash
buffer five times. One hundred microliters of Streptavidin-ALP
diluted 1:1000 was added to each of the wells and the plate
incubated at room temperature in the dark for 1h, followed
by washing five times. Finally, phosphatase substrate (Sigma
Aldrich, Vale Road, Arklow, Ireland) at a final concentration of
1 mg/ml was prepared in de-ionized water supplemented with
7.5 mg/ml glycine, 1 mM ZnCl2 and 1 mM MgCl2 and the pH
adjusted to pH 10.4. One hundred microliters of this substrate
solution was added to each well and the plate incubated at 37◦C
in the dark for 1h. Absorbance readings at 405nm were taken
using a plate reader (Synergy HT, BioTek). IL-8 values were
interpolated using GraphPad Prism software (version 7.0) with
5-parameter logistics.
L. lactis DPC3147 Clearance From Milk
and Detection of Pathogens in Milk
Milk samples were serially diluted in MRD and 50 µl spread
onto the surface of LM17 agar plates and incubated at 30◦C
for 24 h. The cultures were then overlaid with LM17 (1%
agar) containing 1% v/v culture of the lacticin 3147-sensitive
indicator strain L. lactis HP and incubated overnight at 30◦C.
Small white colonies producing a zone of inhibition against the
L. lactis HP overlay were identified as L. lactis DPC3147 and
cfu/ml of DPC3147 remaining in the milk were determined. The
mean cfu/ml values and standard error of mean (SEM) values
were determined. Plating of pathogens from raw milk samples
obtained from high SCC cows was done using Blood agar (Oxoid
Ltd., Basingstoke) (Table 1).
Statistical Analysis
All of the statistical analyses were performed in Graph Pad
Prism v7.0. Comparison of the cure rate of the two treatment
groups was performed using a two-tailed Chi square test.
Comparison of the ‘live bio-therapeutic’ formulation at different
temperatures was done using Two-way ANOVA with Bonferroni
corrections. A one-tailed Mann Whitney test was used to
assess if a significant difference existed between the ‘live
bio-therapeutic’ formulation and antibiotic treatment in the
secretion of IL-8 and SCC/ml in the milk over the course
of the experiment.
RESULTS
The overall aim of this study was to develop a ‘live bio-
therapeutic’ formulation that could be practically administered
on the farm and to compare this to a commercial antibiotic
formulation routinely used to treat mastitis (TerrexineTM). In
order to achieve this, we developed a liquid paraffin-based tube
formulation, similar to tube formulations commonly used for
antibiotic administration.
Short-Term Testing of L. lactis DPC3147
in Various Formulations Reveals Cells
Are Viable for at Least 5 Days
Viability of the L. lactis DPC 3147 cells was investigated
daily for up to 5 days in four formats: (i) non-freeze
dried cells re-suspended after centrifugation in WFI
(Figure 1B); (ii) non-freeze dried cells re-suspended in a liquid
paraffin/polysorbate 80-based emulsion (Figure 1C, ‘live bio-
therapeutic’ formulation); (iii) freeze-dried cells re-suspended
in WFI (Figure 1D) and iv) freeze-dried cells in a liquid
paraffin/polysorbate 80-based emulsion (Figure 1E). Previous
pilot trials had shown that approximately 109 cfu per 5 ml dose
was sufficient to elicit neutrophil influx into the mammary gland
(Crispie et al., 2008). On that basis, we selected 1 × 109 cfu/5 ml
dose (equivalent to 2 × 108 cfu/ml) as we hypothesized that
such a concentration would evoke a sufficiently potent immune
response, without causing any unexpected adverse reactions
in the cows. The results from the short-term viability assays
show that at 4◦C, all the cell preparations maintained viable
cells for up to 5 days (Figures 1B–E). Non-freeze dried cells
in the emulsion (Figure 1C) displayed better viability than
corresponding non-freeze dried cells in WFI (Figure 1B) when
stored at 22◦C and 37◦C. The viability of freeze-dried cells in
emulsions stored at 22◦C and 37◦C (Figure 1E) were more stable
than corresponding freeze-dried cells stored in WFI (Figure 1D).
Both non-freeze dried (Figure 1B) and freeze-dried cells stored
in WFI (Figure 1D) exhibited a drop in viable cells counts within
5 days of storage at 22◦C and 37◦C.
Liquid Paraffin Emulsion-Based
Formulation of DPC3147 Maintains
Viable Cells for Up to 5 Weeks
Determination of the viability of the liquid paraffin-based
emulsion containing L. lactis DPC3147 (‘live bio-therapeutic’
formulation), was assessed by conducting viable plate counts
every 7 days, and showed that the cells remained viable to a
high level for up to 5 weeks. With a starting concentration of
approximately 109 cfu/5 ml dose (2× 108 cfu/ml), cells remained
at approximately 107 cfu/ml even after 5 weeks, when stored at
4◦C (Figure 2). Cell numbers fell to approximately 106 cfu/ml
at 5 weeks, when stored at 22◦C or 37◦C (Figure 2). In this
study, approximately 1× 109 cfu/5 ml dose was selected to ensure
a sufficiently potent immune reaction, based on previous pilot
trials. Two-way ANOVA with Bonferroni corrections showed
that there was no statistically significant difference between the
mean log cfu/ml values for emulsion preparations stored at 4◦C
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TABLE 1 | Cure rates for cases which gave culture-positive milk samples.
Culture-positive Identity of pathogens Cure rate of culture-positive cases based on
Treatment cases SCC results (%)
“Live bio-therapeutic” emulsion
(total N = 19 quarters)
12/19 (63.16%) S. aureus (N = 11), Strep. uberis
(N = 1)
S. aureus 5/11 (45.45%), Strep. uberis 1/1 (100%),
Culture-negative cases 3/7 (42.86%)
Antibiotic (total N = 18 quarters) 12/18 (66.66%) S. aureus (N = 8), Strep. uberis
(N = 2), Strep. dysgalactiae (N = 1),
E. coli (N = 1)
S. aureus 4/8 (50%), Strep. uberis 0/2 (0%), Strep. dysgalactiae 0/1
(0%), E. coli 0/1 (0%), Culture-negative cases 5/6 (83.33%)
The culture of pathogens from cows with mastitis was not successful in every case. Staphylococcus aureus was assumed to be the most probable cause of the high
SCC for milk samples that were found to be culture-negative, on the basis of data collated from routine screening of milk samples from cows with clinical and sub-clinical
mastitis in the Moorepark herd in Teagasc Animal and Grassland Research and Innovation Centre over the years. N = number of quarters infused. Percentages are
indicated in parentheses.
versus 22◦C at any of the time points. Similarly there was no
difference between the means of log cfu/ml values of samples
stored at 4◦C versus 37◦C at any time point (P> 0.05 in all cases)
with the exception of day 28 (P < 0.05).
The “Live Bio-Therapeutic” Formulation
Displays Comparable Efficacy to a
Commercial Antibiotic Product in Curing
Mastitis
Animals with a SCC of >250,000 cells/ml (median SCC of
2,845,929 cells/ml) were selected for this study as they were
representative of clinical or sub-clinical mastitis. These affected
teats were infused with either L. lactis DPC3147 in a liquid
paraffin-based emulsion (‘live bio-therapeutic’ formulation) or
the control commercial antibiotic. While a minimum SCC of
>250,000 cells/ml was chosen as a criterion for selecting cows
with clinical/sub-clinical mastitis, the vast majority of animals
selected had starting SCC significantly higher than this minimum
value (as reflected by a relatively high median SCC value of
2,845,929 cells/ml). Cows were sampled at various time points
over the course of 7 days and cure was considered to be a
FIGURE 2 | Viability of the ‘live bio-therapeutic’ formulation in a liquid
paraffin/polysorbate 80-based emulsion prepared from washed cell
preparation and stored at 4, 22, and 37◦C. Determination of viability of
L. lactis DPC3147 cells in a liquid paraffin-based emulsion (with a final
concentration of 2.5% polysorbate 80) (“live bio-therapeutic’ formulation).
Error bars represent standard deviations of mean values in each case.
reduction in SCC from initially high starting counts (since
median SCC of 2,845,929 cells/ml were approximately 10-fold
higher than final counts after treatment) to an SCC of between
250,000 and 350,000 cells/ml within 5–7 days post-treatment.
It was shown that the efficacy of the ‘live bio-therapeutic’
formulation is similar to the antibiotic (47% vs. 50% cure rate
respectively, P = 0.93, Chi square test) (Figure 3 and Table 2).
Initially after treatment, the ‘live bio-therapeutic’ group had a
significantly higher median SCC than the antibiotic treatment
group (P< 0.05, one-tailed Mann Whitney test, GraphPad Prism
version 7.0) presumably due to the influx of neutrophils into the
mammary gland. However, following 2 days post-infusion, the
difference in the median of the SCC of both treatment groups was
not significant (P > 0.05).
The “Live Bio-Therapeutic” Formulation
Evokes a Relatively Stronger Immune
Response Compared to a Control
Commercial Antibiotic Product
In order to measure the immune response from the treatments,
IL-8 levels were measured in the raw milk samples which were
taken from various cows at different time points pre-and post-
treatment (Figure 4). We selected IL-8 as a bio-marker since
quantitative real-time PCR in previous trials had shown that IL-8
was the most up-regulated cytokine in response to the L. lactis
live bio-therapeutic and other treatment groups. While there
was a large inter-animal variation in IL-8 concentrations, overall,
the peak concentrations, as well as the median values of IL-
8 were greater in the group of animals treated with the ‘live
bio-therapeutic’ preparation, indicating an increased localized
immune response. The median IL-8 values of the ‘live bio-
therapeutic’ group was significantly higher than the control
antibiotic group (P = 0.0454, one-tailed Mann Whitney test,
GraphPad Prism version 7.0, Figure 4A). Similarly, the median
peak values of IL-8 for the ‘live bio-therapeutic’ group were
also significantly higher than the median peak IL-8 values for
the control antibiotics group (P = 0.0042, one-tailed Mann
Whitney test, GraphPad Prism version 7.0, Figure 4B). In
general, the range of IL-8 concentrations were highest within
the first 72 h for both treatment groups following infusion
and subsequently reduced with time, indicating that the most
profound immune response was elicited during this time period
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FIGURE 3 | Median log somatic cell counts/ml in milk samples from groups of cows with mastitis treated with either the “live bio-therapeutic” formulation or the
commercial antibiotic. Determination of SCC from milk samples obtained from cows treated with either the “live bio-therapeutic” emulsion or the commercial
antibiotic. Error bars represent standard error for each of the treatment groups.
for both treatment groups. These results strongly suggest that
the mechanism of action of the ‘live bio-therapeutic’ formulation
involves a stimulation of the immune system as indicated by the
heightened IL-8 response (Figure 4). This host reaction most
likely eliminates the offending pathogen, so that the infection
is reduced and the SCC level subsequently decreases to between
250,000 and 350,000 cells/ml within 5–7 days of treatment.
L. lactis DPC3147 Is Undetectable in Milk
After 5 Days
After cows were infused with the ‘live bio-therapeutic’
preparation, the raw milk samples were tested at intervals
for the presence of viable cells of L. lactis DPC3147. The data
showed that no culturable cells of DPC3147 were detected in
the milk five days post-infusion and that there were on average
<10 cfu/ml in milk just after 1 day of treatment. These results
demonstrate that the animals shed the ‘live bio-therapeutic’ in
the milk in a very short time frame. It is likely that the host
immune response, which is particularly potent within 6–24 h
post-infusion, also results in the clearance of the DPC3147 cells
from the teat, resulting in the relatively low numbers excreted
TABLE 2 | Cure rates for the commercial antibiotic control and the ‘live
bio-therapeutic’ preparation in emulsion.
Treatment N (number of Cure rate (%)
quarters)
Commercial antibiotic 18 50
“Live bio-therapeutic” emulsion preparation 19 47
Cure was considered to be a reduction of SCC to between 250,000 and 350,000
cells/ml within 5–7 days post-treatment.
in the milk. Since the infusion is with initially metabolically
active DPC3147 cells, it is likely that the cells initially begin to
produce lacticin 3147 in these conditions within the teat. We
hypothesize that the concentrations of lacticin 3147 built up
within the teat remain relatively low. However, the metabolically
active cells initially infused likely induce a potent immune
response involving IL-8, which helps to resolve the infection by
clearing the offending pathogen. Overall, the relatively quick
clearance rate, compounded by the fact that L. lactis has been
granted GRAS status as a dairy starter organism, indicates
that milk would not have to withheld post-treatment, unlike
antibiotic treatment, which often results in milk withholding
delays (Figure 5). Although the detection of viable but non-
culturable (VBNC) populations of DPC3147 excreted in milk
was beyond the scope of this study, we hope to investigate such
intermediate viable sub-populations in future trials by using
complementary techniques such as flow cytometry, in addition
to viable plate counts.
The Live Bio-Therapeutic Formulation
Demonstrates Similar Efficacy to a
Commercial Antibiotic Product Against
Specific Pathogens
Staphylococcus aureus was found to be the predominant
etiological agent for mastitis in both the live bio-therapeutic as
well as the TerrexineTM treatment groups. Overall, it was shown
that the efficacy of the live-biotherapeutic in cows infected with
S. aureus (45.45% cure rate) was comparable to the TerrexineTM
treatment group (50% cure rate). Further follow-up trials with a
greater N number will provide insights into the relative efficacy
of the live bio-therapeutic and TerrexineTM against specific
mastitis-causing pathogens.
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FIGURE 4 | IL-8 concentrations quantified in milk samples from mastitic cows treated with the ‘live bio-therapeutic’ formulation or the commercial antibiotic.
(A) Determination of median IL-8 titres (pg/ml) by ELISA from various milk samples obtained from different cows over time. These cows displayed mastitis and were
treated with either the ‘live bio-therapeutic’ emulsion or the commercial antibiotic. (B) Peak IL-8 concentrations in milk samples obtained from various cows treated
for clinical/sub-clinical mastitis with either the ‘live bio-therapeutic’ formulation or the commercial antibiotic. Each dot represents milk samples obtained from different
quarters treated with the above-mentioned therapies.
DISCUSSION
In this study, we evaluated the effectiveness of a ‘live bio-
therapeutic’ (an emulsion-based formulation of non-freeze dried
L. lactis DPC3147) compared to a commercial antibiotic control
for treating cows with clinical/sub-clinical mastitis. We selected
non-freeze dried cells for the ‘live bio-therapeutic’ emulsion
FIGURE 5 | L. lactis DPC3147 clearance from milk. Determination of the rate
of clearance of L. lactis DPC3147 from milk samples from a selection of cows
treated with the ‘live bio-therapeutic’ formulation in emulsion. Graph shows
mean values and standard error of mean (SEM).
formulation primarily due to the relative ease of formulating
freshly prepared emulsions containing non-freeze dried cells,
compared to freeze-dried cells. While previous studies by our
group had already highlighted the efficacy of DPC3147 aqueous-
based formulations as potential therapeutic options for curing
mastitis, some key objectives of the present study were (i) to
develop and evaluate a formulation that would be ready to use
by the farmer; (ii) to compare a single application of the ‘live bio-
therapeutic’ formulation to a double application of a commercial
antibiotic; (iii) evaluate the efficacy of the ‘live bio-therapeutic’
formulation against a commercial antibiotic which is commonly
used on Irish farms and finally iv) to follow the fate of the
introduced live bio-therapeutic following application.
The long-term viability of such a live bio-therapeutic emulsion
is likely to be a crucial factor governing the success of the live
bio-therapeutic as an alternative therapeutic agent. In this regard,
it must be noted that strategies involving liquid paraffin-based
emulsions have already been exploited for encapsulating other
products including antibiotics, non-steroidal anti-inflammatory
drugs (NSAIDS), cisplatin and insulin (Giri et al., 2013). In
order for our emulsion-based ‘live bio-therapeutic’ formulation
to be successful, the L. lactis cells must diffuse out of the
droplets quickly into the infected mammary gland to evoke
a potent immune response. An important factor determining
diffusion rate in an emulsion is the volume of the droplets,
due to the higher volume: surface area ratio of the droplets. It
was encouraging to note in this present study that the viability
of L. lactis DPC3147 remained relatively high in the ‘live bio-
therapeutic’ formulation, for a period of 5 weeks when stored at
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4, 22, and 37◦C, indicating that the cells remain viable embedded
in the lipid droplets. A long-term viable product of this nature
could prove to be highly beneficial to farmers attempting to
cure mastitis and is under development in our laboratory. It
should also be emphasized that this product when applied in
applicator tubes is in a ‘ready to use’ form by the farmer and
can be introduced into the animal without any modification.
However, as the properties of the bacterial cell surface might be
altered following a period of prolonged storage, it is envisaged
that the focus of future field trials in our group will involve
testing the efficacy of such emulsion-based formulations after
long-term storage, compared to freshly prepared emulsions of the
same strain.
As a means of evaluating the success of the ‘live bio-
therapeutic’ formulation, we assessed the effects of this emulsion-
based formulation and the commercial antibiotic control on
the SCC of cows presenting with clinical/sub-clinical mastitis
in this trial. SCC is the standard bio-marker associated
with mastitis infection and can be used as an indication of
disease (Klostermann et al., 2008). Our group had previously
demonstrated that intra-mammary infusion with viable L. lactis
DPC3147 in WFI was effective at treating sub-clinical and
clinical mastitis, with up to 60% cure rates in terms of
eliminating signs of clinical mastitis, which was comparable
to antibiotic efficacy in the trial (Klostermann et al., 2008).
On this basis, we evaluated whether our novel emulsion-
based formulation of viable DPC3147 cells was also effective
in treating cows with mastitis. Similar to the findings of
Klostermann and co-workers, we found that the cure rate of
cows treated with the ‘live bio-therapeutic’ (47% cure rate)
was comparable to commercial antibiotics (we obtained a
50% cure rate for the commercial antibiotic control group
in this study, which was the expected cure rate), in terms
of reducing SCC/ml five to 7 days post-infusion. In the
present study, we noted an initial spike in SCC/ml 6-24h
after infusion of the ‘live bio-therapeutic’ formulation, which
indicates an induction of a localized immune response. The
SCC counts returned to pre-infusion levels or lower than initial
levels, within 7 days of treatment, which corroborated previous
findings describing transient elevations in SCC counts shortly
after infusion (Crispie et al., 2008; Klostermann et al., 2008;
Beecher et al., 2009).
With respect to the mechanism of action of L. lactis
DPC3147 cells in potentially treating mastitis, a previous study
by Crispie et al., showed that unlike DPC3147 cells, intra-
mammary infusion of cell-free supernatant (CFS) from lacticin
3147-producing cultures did not evoke a potent immune
response (Crispie et al., 2008). Therefore, we hypothesized that
the immune-stimulatory effect is likely to be predominantly
cell-associated and not solely due to the presence of the
bacteriocin. With this in mind, we compared the IL-8 titres in
milk samples from cows treated with the ‘live bio-therapeutic’
emulsion containing viable L. lactis DPC3147 cells to the control
commercial antibiotic in this trial. IL-8 was chosen as it was the
most up-regulated cytokine in milk upon infusion with the ‘live
bio-therapeutic’ in previous trials (Crispie et al., 2008). Despite a
large inter-animal variation in IL-8 titres in milk as a result of
‘live bio-therapeutic’ infusion, the results demonstrate that the
peak concentrations as well as the median values of IL-8 were
greater in cows treated with this ‘live bio-therapeutic’ preparation
compared to the commercial antibiotic group, suggesting a
more potent immune response elicited by DPC3147 cells. In
general, the range of IL-8 concentrations was highest within
the first 72h after infusion and subsequently reduced with
time, suggesting that the most profound immune response was
evoked during this time period. This corroborated previous
findings by Crispie et al., who demonstrated that intra-mammary
infusion of DPC3147 induced the recruitment of neutrophils,
providing an additional immunological defence against mastitis-
causing pathogens. Indeed, a key function of IL-8 is to recruit
polymorphonuclear leukocytes (neutrophils) as well as other
immune cells to the site of infection, assisting in the resolution
of the infection.
It is interesting to note that previous studies by Bannerman
and co-workers, as well as Yang and co-workers, had
demonstrated that while the Gram negative mastitis-causing
pathogen E. coli elicited increases in IL-8 expression, perhaps
the most common mastitis-causing pathogen, S. aureus, failed to
trigger such an effect (Bannerman et al., 2004; Yang et al., 2008).
Indeed, a failure to evoke a potent immune reaction in response
to S. aureus may contribute to its widespread persistence as an
etiological agent of recurrent mastitis. A study of a similar nature
by Beecher and co-workers showed that while the pathogen Strep.
dysgalactiae induced a modest increase in IL-8 gene expression,
the ‘live bio-therapeutic’ L. lactis DPC3147 triggered a more
potent immune response, compared to the pathogens tested in
the study (Beecher et al., 2009). Thus, the immune-stimulatory
activity of ‘live bio-therapeutic’ containing viable L. lactis
DPC3147 cells is likely to be the main mechanism of action
which explains its efficacy in this and previous trials. Although
the concentration of lacticin 3147 produced by the DPC3147 cells
in the teat was not measured in this trial, we hypothesize that
the concentrations would be relatively low upon infusion, as the
DPC3147 cells would require enough time to produce sufficient
concentrations of the peptides to kill the offending pathogen.
The concentrations of bacteriocin produced in the teat will have
to be quantified in future field trials of this nature, perhaps by
measuring the concentrations excreted in milk, in order to gain
insights as to whether the presence of the bacteriocin peptides
contribute to the immune-stimulatory effect and apparent
resolution of the disease or not. In addition, follow-up field
trials are currently being conducted, testing the effects of a
bacteriocin-negative derivative of L. lactis DPC3147 (i.e., L. lactis
DPC 5399, devoid of the pMRC01 plasmid and the lacticin
3147 biosynthetic machinery) to elucidate whether bacteriocin
production is vital for inducing an immune response or not.
Irrespective of bacteriocin production, we hypothesize that the
concentrations of the peptides present in the teat are relatively
low and at sub-inhibitory concentrations, and thus unlikely to
exert a direct antimicrobial effect on the offending pathogen.
This warrants further investigation in future field trials, which
will focus on precisely quantifying the concentrations of the
peptides in vivo to fully unravel the complex mechanism of
action of treating this disease.
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Overall, the potential use of the ‘live bio-therapeutic’ as
a viable alternative in lieu of commercial antibiotics presents
some notable advantages. Significantly, several commercial
antibiotic formulations must be administered using two doses,
which frequently results in delays in the milking process
to re-commence. In contrast, by utilizing a single dose of
the ‘live bio-therapeutic’ formulation, one could hasten the
re-commencement of milking, in turn resulting in reduced
economic losses. In addition, the current practice of discarding
milk following antibiotic treatment due to the presence of
residues is unlikely be an issue following treatment with the ‘live
bio-therapeutic’ formulation since the organism is food-grade.
Moreover, in this trial, we have demonstrated that DPC3147 cells
are completely cleared from milk within 5 days of infusion, most
likely as a consequence of the immune response. Furthermore,
the relatively inexpensive nature of the ‘live bio-therapeutic’
formulation can help to reduce overall costs involved in treating
bovine mastitis. Despite its history of safe use as a dairy starter
organism, the strain L. lactis DPC3147 must fulfill a number
of criteria before being granted Qualified Presumption of Safety
(QPS) status by the European Food Safety Authority (EFSA)
as a bio-therapeutic. One key example of such a criterion
includes the absence of transmissible antibiotic resistance genes
on mobilizable elements. In addition, the strain must not possess
any virulence factors or have the propensity to cause any
opportunistic infections, whilst being considered for QPS status
as a bio-therapeutic.
In conclusion, we have developed a ready to use formulation
which proved as efficacious as antibiotic treatment for mastitis
treatment. The findings described in this study warrant further
investigations in future field trials to fully unravel the complex
mechanisms of action involved in the treatment of bovine
mastitis. Indeed, an assessment of the efficacy of a heat-killed
emulsion-based formulation of the DPC3147 is the focus of
a follow-up field trial in our group. We hope that this will
provide insights into the mechanism of action of the product
and whether the cells have to be viable or not to elicit an equally
potent immune-stimulatory effect. An equally potent immune-
stimulatory effect induced by heat-killed cells of the strain would
obviate the need to prepare fresh viable cells and any concerns
regarding the long-term viability of the cells. Furthermore,
future field trials of this nature warrant precise identification
of the offending pathogen using DNA-based methodology, as
the identification of pathogens using a culture-based method
is rather limited. The creation of bio-banks of mastitis-causing
pathogens, and precise identification of such strains as part
of future trials, would help in determining the lacticin 3147
sensitivity/resistance patterns of these pathogenic strains. Finally,
subject to ethical approval by local Animal Ethics Committees,
we hope to investigate whether administering two injections of
the live bio-therapeutic formulation proves more efficacious than
a single dose, as part of future trials. Nonetheless, overall, the
implications of the findings described here could eventually lead
to a significant reduction of antibiotics for treatment of this most
persistent disease in dairy cows.
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